Shares of Herbalife have fallen more than 35 percent this year. Tim Ramey, Pivotal Research analyst, explains his $110 price target on the stock.» Read More
Some of the names on the move ahead of the open.
Rumack: Can you fly this plane, and land it? Ted Striker: Surely you can't be serious. Rumack: I am serious... and don't call me Shirley. -Airplane Below, Boeing's Dreamliner woes become more serious, as the FAA temporarily grounds all 787 planes.
Billionaire Carl Icahn is telling other investors he has bought a stake in nutritional supplements seller Herbalife, according to a Dow Jones report on Wednesday.
According to the Dow Jones, Carl Icahn has taken a stake in Herbalife, reports CNBC's Herb Greenberg.
Take a look at some of Monday's midday movers:
Take a look at some of Friday's midday movers:
A fiscal-cliff driven sales boom in Malibu has made the California beach retreat the nation's likely leader for homes worth $10 million-plus.
Herbalife shares are attractive despite high-profile short interest in the stock, Kerrisdale Capital's Sahm Adrangi says.
Herbalife's annual growth rate makes the stock attractive at its current level, Kerrisdale Capital Management Founder Sahm Adrangi says.
Sahm Adrangi, Kerrisdale Capital Management, explains why he took a long position on Herbalife when the stock was trading at $26.
Stocks extended their gains in the final hour of trading to close near session highs Thursday, with all key S&P sectors finishing in positive territory, but volume was light amid caution ahead of next week's flurry of earnings report.
Herbalife ratcheted up its defense against activist investor Bill Ackman, with CNBC's Brian Shactman.
Herbalife is fighting back against Bill Ackman with an investor day today, reports CNBC's Herb Greenberg.
"Let's be honest with each other, here," Herbalife CEO Michael Johnson told CNBC Thursday. "He's going to donate all of his profits to charity? He's got participants in that(hedge) fund...Who knows where it's really going?"
Bill Ackman says "we will respond to every issue raised by Herblife." CNBC's Herb Greenberg reports.
Herablife will file an update on Q4 performance next week. CNBC's Herb Greenberg discusses his interview with Herbalife CEO Michael Johnson.
Michael Johnson, Herbalife CEO, discusses his company's business model and explains how distributors receive compensation, with CNBC's Kate Kelly.
Two of the richest and most prominent hedge fund managers in Manhattan are locked in a battle over nutritional supplement provider Herbalife. The New York Times reports.
CNBC's Herb Greenberg explains why the drama with Herbalife is far from over. And CNBC's Kate Kelly provides an update on the company from the analyst meeting.
Herbalife President Des Walsh told CNBC on Thursday that hedge fund manager Bill Ackman's allegations are completely false.